DrugPatentWatch Database Preview
Atropine sulfate - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for atropine sulfate and what is the scope of freedom to operate?
Atropine sulfate
is the generic ingredient in seventeen branded drugs marketed by Us Army, Akorn, Alcon Labs Inc, Accord Hlthcare, Hospira, Intl Medication Sys, Fresenius Kabi Usa, Sebela Ireland Ltd, Scherer Rp, Medpointe Pharm Hlc, Hikma, Alpharma Us Pharms, Gd Searle Llc, Md Pharm, Able, Ani Pharms Inc, Ascot, Bayshore Pharms Llc, Eci Pharms Llc, Fosun Pharma, Heather, Inwood Labs, Kv Pharm, Lannett, Leading Pharma Llc, Lederle, Mayne Pharma Inc, Mylan, Par Pharm, Parke Davis, Pvt Form, R And S Pharma, Roxane, Specgx Llc, Sun Pharm Industries, Upsher Smith Labs, Usl Pharma, Valeant Pharm Intl, Watson Labs, Vangard, Superpharm, Pfizer, Halsey, Mylan Institutional, Abbvie, and Wyeth Ayerst, and is included in fifty-two NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-three drug master file entries for atropine sulfate. Nine suppliers are listed for this compound.
Summary for atropine sulfate
| US Patents: | 0 |
| Tradenames: | 17 |
| Applicants: | 46 |
| NDAs: | 52 |
| Drug Master File Entries: | 23 |
| Suppliers / Packagers: | 9 |
| Bulk Api Vendors: | 111 |
| Clinical Trials: | 30 |
| Patent Applications: | 6,311 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in atropine sulfate? | atropine sulfate excipients list |
| DailyMed Link: | atropine sulfate at DailyMed |
Recent Clinical Trials for atropine sulfate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Sao Paulo General Hospital | Phase 3 |
| Fayoum University | Phase 1 |
| Ain Shams University | N/A |
Pharmacology for atropine sulfate
| Drug Class | Anticholinergic Cholinergic Muscarinic Antagonist |
| Mechanism of Action | Cholinergic Antagonists Cholinergic Muscarinic Antagonists |
US Patents and Regulatory Information for atropine sulfate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Institutional | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019678-001 | Nov 6, 1991 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Ascot | DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE | atropine sulfate; diphenoxylate hydrochloride | TABLET;ORAL | 087934-001 | Jul 19, 1983 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Abbvie | ATROPINE AND DEMEROL | atropine sulfate; meperidine hydrochloride | INJECTABLE;INJECTION | 087847-001 | Nov 26, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Hospira | ATROPINE SULFATE | atropine sulfate | SOLUTION;INTRAVENOUS | 021146-005 | Aug 17, 2017 | AA | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
